Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma

被引：17
|
作者：
Gautschi, Oliver [1 ]
Menon, Roopika [2 ]
Bertrand, Miriam [2 ]
Murer, Christian [1 ]
Diebold, Joachim [1 ]
机构：
[1] Cantonal Hosp Lucerne, Luzern, Switzerland
[2] NEO New Oncol GmbH, Cologne, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2019.07.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E13 / E15
页数：4
相关论文
共 50 条
  • [1] Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Mehta, Anurag
    Jain, Parveen
    Bansal, Abhishek
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (01):
  • [2] EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
    Hara, Reina
    Kanazu, Masaki
    Iwai, Ami
    Kuge, Tomoki
    Ishijima, Mikako
    Uenami, Takeshi
    Akazawa, Yuki
    Yano, Yukihiro
    Yamaguchi, Toshihiko
    Mori, Masahide
    THORACIC CANCER, 2021, 12 (09) : 1441 - 1444
  • [3] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [4] Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
    Wilgucki, Molly
    Yeung, Vincent
    Ho, Grace
    Montenegro, Gabriela L. Bravo
    Jones, Greg
    Reuss, Joshua E.
    V. Liu, Stephen
    Kim, Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (10):
  • [5] A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
    Takano, Natsuki
    Seike, Masahiro
    Sugano, Teppei
    Matsuda, Kuniko
    Hisakane, Kakeru
    Yoshikawa, Akiko
    Nakamichi, Shinji
    Noro, Rintaro
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2022, 42 (02) : 709 - 722
  • [6] ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers
    Fan, Pang-Dian
    Yu, Helena A.
    CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5499 - 5501
  • [7] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [8] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
    Oztan, A.
    Fischer, S.
    Schrock, A. B.
    Erlich, R. L.
    Lovly, C. M.
    Stephens, P. J.
    Ross, J. S.
    Miller, V.
    Ali, S. M.
    Ou, S. -H. I.
    Raez, L. E.
    LUNG CANCER, 2017, 111 : 84 - 87
  • [9] Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
  • [10] Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report
    Thanasombunsukh, K.
    Chamnongprasatporn, B.
    Chiravirakul, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S649 - S650
12345